Today: 21 May 2026
Browse Category

BSE:PWL 1 December 2025

PhysicsWallah Ltd (PWL) Share Price Today: From Blockbuster IPO Debut to Sharp Pullback – Latest News and Analyst View (1 December 2025)

PhysicsWallah Ltd (PWL) Share Price Today: From Blockbuster IPO Debut to Sharp Pullback – Latest News and Analyst View (1 December 2025)

PhysicsWallah Ltd (PWL) traded near ₹131.4 per share on 1 December 2025, valuing the edtech firm at about ₹37,576 crore. The stock has dropped nearly 19% from its post-listing high of ₹161.99 but remains above its IPO price of ₹109. PWL’s trailing P/E is negative, P/B ratio stands at 9.3, and it pays no dividend. Trendlyne flagged the stock as “Expensive Valuation” and “Technically Bearish.”
1 December 2025
···

Stock Market Today

  • Stock Market Today: Key Insights for May 21 Trading
    May 20, 2026, 10:27 PM EDT. Stocks in the news and major brokerage calls shape market sentiment as traders prepare for May 21. This report provides a complete trade setup, highlighting critical market movements and strategies. Stay informed with the essential data before entering trades today.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop